Please login to the form below
Prescription Digital Therapeutics
This page shows the latest Prescription Digital Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Pear Therapeutics submits latest digital therapeutic, insomnia and depression treatment
Pear Therapeutics is a pioneer of so-called digital therapeutics, having gained the first ever such approval from the FDA in 2017, for its treatment for patients with Substance Use Disorder ... Its Prescription Digital Therapeutics (PDTs) are app-based
Latest news
-
FDA clears Sandoz and Pear’s Opioid Use Disorder app
validated software-based therapeutics, known as Prescription Digital Therapeutics (PDT). ... Richard Francis, CEO, Sandoz. "New digital therapeutics such as reSET-O also have the potential to fundamentally change how patients interact with their
-
Novartis plans digital therapeutics for schizophrenia and MS
Novartis shares our vision for prescription digital therapeutics that work alongside drugs to deliver superior patient outcomes. ... We believe this collaboration further supports the clinical viability of prescription digital therapeutics as an emerging
-
FDA approves first substance use mobile medical application
Corey McCann, Pear’s president and CEO, said: “This is a defining moment for digital therapeutics and for patients with substance use disorder. ... We believe that prescription digital therapeutics hold promise in improving patient outcomes across a
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Impetus Digital Fireside Chat with with Jon Sockell, Co-Founder/COO of Limbix
Limbix Spark is the first prescription digital therapeutic designed to support adolescents with depression. ... See how Limbix is paving the way for prescription digital therapeutics and learn from their trials, tribulations, successes, and vision for
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Eli Lilly begins COVID-19 prevention trial in nursing homes
- New study identifies drugs that are safe to use in COVID-19 treatment
- Biogen pays Denali $1bn upfront for Parkinson’s disease programme
- Tecentriq combo fails in advanced triple negative breast cancer
- Bristol-Myers Squibb’s revenues rise on Celgene acquisition
- Novartis builds its case for novel MS treatment ofatumumab
- Virtual Hackathon on Healthcare Innovation: a Customer Story
- OPEN Health at the World Orphan Drug Conference USA
- US pays $1.5bn for 100 million doses of Moderna’s COVID-19 vaccine
- Vir Biotech plans to start mid-to-late stage study of COVID-19 antibody this month
- Russia becomes first country to approve a COVID-19 vaccine
- Can involving patients in design transform the clinical trial experience?
PMHub
Empowering Strategic Performance Ltd
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...
Latest intelligence
- Virtual Hackathon on Healthcare Innovation: a Customer Story
- How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
- OPEN Health at the World Orphan Drug Conference USA
- Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
- Can involving patients in design transform the clinical trial experience?
- While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...
Quick links
Infographics
